In Conversation With Scientist and CRISPR Pioneer Jennifer Doudna
Posted by btwatson on January 27, 2018 10:07 pm
Tags:
Categories:
Crispr
In Conversation With Scientist and CRISPR Pioneer Jennifer Doudna
Join Susan MacTavish Best in discussion with Jennifer Doudna. You’ll hear about gene editing and how the technology surrounding it has evolved.
Crispr News
-
Researchers use CRISPR technology to modify starches in potatoes - Phys.orgMay 25, 2022
-
Where Does Wall Street Think Crispr Therapeutics AG (CRSP) Stock Will Go? - InvestorsObserverMay 25, 2022
-
Plant Breeding and CRISPR Plants Market Size And Forecast | Bayer, Syngenta, KWS, DowDuPont, Eurofins, SGS, Advanta Seeds, Benson Hill Biosystems, Bioconsortia, DLF – The Daily Vale - The Daily ValeMay 25, 2022
-
On the record – modified bacteria can capture gut health status - Longevity.TechnologyMay 25, 2022
-
Cell Theraputics Market Share and Size 2022 By Type, By Application, and By Region | Key Players Quanterix, PTC Therapeutics, Moderna Therapeutics, Lineage Cell Therapeutics, Cti Biopharma, Crispr Therapeutics, Bluebird Bio – The Daily Vale - The Daily ValeMay 25, 2022
-
CRISPR-PE Technology Market Research With Beam Therapeutics, CRISPR Therapeutics, GenScript Biotech, Horizon Discovery, Integrated DNA Technologies (IDT | Cumulative Report 2022 Impact of COVID-28 – The Daily Vale - The Daily ValeMay 25, 2022
-
Breakthrough CRISPR-Combo edits some genes and activates others - New AtlasMay 25, 2022
-
Gene Editing Service Market Increasing Demand and Dynamic Growth with Forecast 2029 | BBI Life Sciences, Bio Basic, CRISPR Therapeutics, Caribou Biosciences, DNA 2.0 (ATUM) – The Daily Vale - The Daily ValeMay 25, 2022
-
UK uses Brexit freedom to speed up the development of 'gene-edited' crops and livestock - Daily MailMay 24, 2022
-
Clustered Regularly Interspaced Short Palindromic Repeats(CRISPR) Technology Market Size And Forecast | Thermo Fisher Scientific, Merck, GenScript, Integrated DNA Technologies, Horizon Discovery Group, Agilent Technologies, Cellecta, GeneCopoeia, - The Daily ValeMay 24, 2022
-
Goldman Sachs Maintains Neutral on CRISPR Therapeutics, Lowers Price Target to $46 - Benzinga - BenzingaMay 24, 2022
-
CRISPR tomatoes genetically engineered to be richer in vitamin D - New AtlasMay 24, 2022
-
Gene Editing Service Market Size 2022 Overview by 2029 | Key Players – BBI Life Sciences, Bio Basic, CRISPR Therapeutics, Caribou Biosciences, DNA 2.0 (ATUM) – The Daily Vale - The Daily ValeMay 24, 2022
-
CRISPR Editing Accidentally Turns Hamsters Into Angry Bullies - IFLScienceMay 23, 2022
-
Piper Sandler Maintains Overweight on CRISPR Therapeutics, Lowers Price Target to $115 - Benzinga - BenzingaMay 23, 2022
- CRISPR rivals put patents aside to help in fight against Covid-19 – STAT
- CRISPR 2.0: Base Editing in the Groove – Genetic Engineering & Biotechnology News
- The Promises of CRISPR Genome Editing in Biomedicine – Labiotech.eu
- The Code Breaker and Crispr People — the ethics of editing humanity – Financial Times
- ERS Genomics Licenses CRISPR Patents to CRO ZeClinics – GenomeWeb
- The Dark Side of CRISPR – Scientific American
- ERS Genomics and ZeClinics Sign CRISPR/Cas9 License Agreement – BioSpace
- Scientists Use CRISPR To Create Model of AML Progression – AJMC.com Managed Markets Network
- DECODR app identifies DNA mutations from CRISPR gene therapies – European Pharmaceutical Review
- CRISPR/Cas technology as a promising weapon to combat viral infections – Wiley
- Neanderthal-like ‘mini-brains’ created in lab with CRISPR – Nature.com
- Affordable CRISPR app reveals unintended mutations at site of CRISPR gene repair – Phys.org
- Affordable CRISPR app reveals unintended mutations at site of CRISPR gene repair – EurekAlert
- New CRISPR tech targets human genome’s complex code: Programmable CRISPR/Cas9-based kinase offers insights into, control over regulatory histone proteins – Science Daily
- After ditching Editas, AbbVie taps Caribou for new CRISPR, CAR-T pact – FierceBiotech
Leave a Reply
You must be logged in to post a comment.